Functions of CJC 1295 w DAC
Growth hormone releasing hormone (GHRH) has been modified a number of times to produce analogues that preserve some of the hormone’s effects while eliminating others. One of those modifications, CJC-1295, consists of just the first 29 amino acids of GHRH. This analogue of GHRH, which is technically a maleimido derivative of hGRF(1-29), was created in an effort to produce a more soluble GH secretagogue that is easier to produce in large quantities but still preserves the physiologic actions of GHRH.
CJC-1295 Versus CJC-1295 DAC
CJC-1295 is a modified version of the first 29 amino acids of GHRH, which means it is chemically similar to other GHRH analogues, like Sermorelin. It is most similar to modified GRF (1-29), but the two peptides are not identical. A great deal of confusion arises because of the similarities between these peptides and because CJC-1295 was originally created with an added chemical compound called the drug affinity complex (DAC).
DAC is added to the molecule, with the help of a lysine linker, to protect the peptide while it circulates in the blood stream. By allowing peptides to bind to the common blood protein albumin, DAC helps to ensure that the half-life of CJC-1295 is much longer than similar molecules like GRF (1-29).
Half-life of CJC-1295-DAC compared to standard growth hormone releasing factor (GRF)
Source: Oxford Academic
Originally, ConjuChem Biotechnologies, the developer of DAC, referred to the molecule containing DAC as simply CJC-1295. Confusion arose, however, because the peptide was also being offered without DAC. To avoid confusion, CJC-1295 that contains DAC is called CJC-1295-DAC and when it does not contain DAC it is referred to as CJC-1295 or CJC-1295-no DAC.
Key Information about CJC-1295
Mechanism of Action:
CJC-1295 is a synthetic peptide designed to mimic the activity of growth hormone-releasing hormone (GHRH). GHRH stimulates the release of growth hormone (GH) from the pituitary gland, a hormone involved in growth, metabolism, and various physiological processes.
Difference Between CJC-1295 and Modified GRF (1-29):
CJC-1295 is a modified version of the first 29 amino acids of GHRH, similar to other GHRH analogs such as Sermorelin. It is particularly similar to modified GRF (1-29), but with some differences in structure. The primary distinction is that CJC-1295, especially when used with DAC (Drug Affinity Complex), has a longer half-life compared to modified GRF (1-29). This allows CJC-1295 to stay in the system longer.
Half-Life:
CJC-1295 is known for its extended half-life, particularly in its DAC form. The addition of DAC allows CJC-1295 to bind to the protein albumin, which may extend its presence in the body. CJC-1295-DAC has been shown to remain in circulation for a longer period than its non-DAC counterpart and similar peptides like modified GRF (1-29).
Safety and Side Effects:
While CJC-1295 has been researched for its potential applications, some users have reported side effects, including water retention, injection site reactions, fatigue, or increased hunger. However, more studies are needed to understand the long-term safety profile of the peptide.
Research Status:
CJC-1295 is currently not approved by the FDA for clinical use in humans. It is primarily used for research purposes, and its use in clinical settings remains limited to experimental studies. There are ongoing investigations into its effects, but more robust human trials are required to confirm its safety and efficacy.
Combination with Other Peptides:
CJC-1295 has been studied alongside other peptides, such as Ipamorelin, in some research settings. Ipamorelin works on different receptors involved in growth hormone release. While combinations of peptides have been explored in research, there is limited clinical data, and further studies are needed to better understand any interactions or outcomes associated with their combined use.
